Is Eterna Therapeutics Stock a Good Investment?
Eterna Therapeutics Investment Advice | ERNA |
- Examine Eterna Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Eterna Therapeutics' leadership team and their track record. Good management can help Eterna Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Eterna Therapeutics' business and its evolving consumer preferences.
- Compare Eterna Therapeutics' performance and market position to its competitors. Analyze how Eterna Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Eterna Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Eterna Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Eterna Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Eterna Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Eterna Therapeutics Stock
Researching Eterna Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was currently reported as 0.41. The company recorded a loss per share of 8.31. Eterna Therapeutics had not issued any dividends in recent years. The entity had 1:20 split on the 17th of October 2022.
To determine if Eterna Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Eterna Therapeutics' research are outlined below:
| Eterna Therapeutics generated a negative expected return over the last 90 days | |
| Eterna Therapeutics has high historical volatility and very poor performance | |
| Eterna Therapeutics has some characteristics of a very speculative penny stock | |
| Eterna Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 68 K. Net Loss for the year was (21.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eterna Therapeutics currently holds about 19.41 M in cash with (20.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.6, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Eterna Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: ERNA Stock Hits 52-Week Low at 0.52 Amid Market Challenges - Investing.com |
Eterna Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Eterna Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eterna Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Eterna Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Eterna Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-10-10 | 2019-09-30 | -0.03 | -0.12 | -0.09 | 300 | ||
2022-11-14 | 2022-09-30 | -2.2 | -2.49 | -0.29 | 13 | ||
2019-05-13 | 2019-03-31 | 0.2 | -0.11 | -0.31 | 155 | ||
2020-03-19 | 2019-12-31 | 0.01 | -0.45 | -0.46 | 4600 | ||
2021-11-09 | 2021-09-30 | -1.6 | -2.2 | -0.6 | 37 | ||
2022-04-15 | 2022-03-31 | -2.5 | -3.2 | -0.7 | 28 | ||
2021-12-31 | 2021-12-31 | -2.5 | -3.2 | -0.7 | 28 | ||
2023-05-11 | 2023-03-31 | -0.14 | -1.24 | -1.1 | 785 |
Know Eterna Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eterna Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eterna Therapeutics backward and forwards among themselves. Eterna Therapeutics' institutional investor refers to the entity that pools money to purchase Eterna Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 100.0 | Activest Wealth Management | 2024-06-30 | 50.0 | Bank Of America Corp | 2024-06-30 | 29.0 | Royal Bank Of Canada | 2024-06-30 | 22.0 | Group One Trading, Lp | 2024-06-30 | 19.0 | Citigroup Inc | 2024-09-30 | 15.0 | Jpmorgan Chase & Co | 2024-06-30 | 14.0 | Aspire Private Capital, Llc | 2024-09-30 | 10.0 | Qube Research & Technologies | 2024-06-30 | 4.0 | Cypress Point Wealth Management, Llc | 2024-09-30 | 94.4 K | Naviter Wealth, Llc | 2024-09-30 | 78.8 K |
Eterna Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 26.71 M.Market Cap |
|
Eterna Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.50) | (0.52) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (9.70) | (9.22) |
Determining Eterna Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Eterna Therapeutics is a good buy. For example, gross profit margin measures Eterna Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Eterna Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Eterna Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Eterna Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Eterna Therapeutics' management manipulating its earnings.
Evaluate Eterna Therapeutics' management efficiency
Eterna Therapeutics has return on total asset (ROA) of (0.2942) % which means that it has lost $0.2942 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.5418) %, meaning that it created substantial loss on money invested by shareholders. Eterna Therapeutics' management efficiency ratios could be used to measure how well Eterna Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.48. In addition to that, Return On Capital Employed is expected to decline to -0.52. At present, Eterna Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 41.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 114 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.42 | 0.40 | |
| Tangible Book Value Per Share | 0.04 | 0.03 | |
| Enterprise Value Over EBITDA | (2.20) | (2.09) | |
| Price Book Value Ratio | 4.28 | 4.42 | |
| Enterprise Value Multiple | (2.20) | (2.09) | |
| Price Fair Value | 4.28 | 4.42 | |
| Enterprise Value | 149.7 M | 157.2 M |
Leadership effectiveness at Eterna Therapeutics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 7.767 |
Basic technical analysis of Eterna Stock
As of the 25th of November, Eterna Therapeutics shows the Standard Deviation of 6.32, variance of 39.91, and Mean Deviation of 4.6. Eterna Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Eterna Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eterna Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eterna Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eterna Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Eterna Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Eterna Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.20) | |||
| Market Risk Adjusted Performance | (1.15) | |||
| Mean Deviation | 4.6 | |||
| Coefficient Of Variation | (368.44) | |||
| Standard Deviation | 6.32 | |||
| Variance | 39.91 | |||
| Information Ratio | (0.29) | |||
| Jensen Alpha | (1.90) | |||
| Total Risk Alpha | (2.72) | |||
| Treynor Ratio | (1.16) | |||
| Maximum Drawdown | 39.97 | |||
| Value At Risk | (12.96) | |||
| Potential Upside | 7.84 | |||
| Skewness | 0.4775 | |||
| Kurtosis | 2.64 |
| Risk Adjusted Performance | (0.20) | |||
| Market Risk Adjusted Performance | (1.15) | |||
| Mean Deviation | 4.6 | |||
| Coefficient Of Variation | (368.44) | |||
| Standard Deviation | 6.32 | |||
| Variance | 39.91 | |||
| Information Ratio | (0.29) | |||
| Jensen Alpha | (1.90) | |||
| Total Risk Alpha | (2.72) | |||
| Treynor Ratio | (1.16) | |||
| Maximum Drawdown | 39.97 | |||
| Value At Risk | (12.96) | |||
| Potential Upside | 7.84 | |||
| Skewness | 0.4775 | |||
| Kurtosis | 2.64 |
Consider Eterna Therapeutics' intraday indicators
Eterna Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Eterna Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Eterna Therapeutics time-series forecasting models is one of many Eterna Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Eterna Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Eterna Stock media impact
Far too much social signal, news, headlines, and media speculation about Eterna Therapeutics that are available to investors today. That information is available publicly through Eterna media outlets and privately through word of mouth or via Eterna internal channels. However, regardless of the origin, that massive amount of Eterna data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Eterna Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Eterna Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Eterna Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Eterna Therapeutics alpha.
Eterna Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Eterna Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Eterna Therapeutics Corporate Management
| Andrew Jackson | Chief Officer | Profile | |
| Robert MD | Chief Officer | Profile | |
| Susan McClatchey | VP Quality | Profile | |
| Sandra Gurrola | Principal Finance | Profile | |
| Megan Yung | Chief Officer | Profile | |
| Roger MD | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.31) | Revenue Per Share 0.03 | Return On Assets (0.29) | Return On Equity (11.54) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Eterna Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.